AUTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Autolus Therapeutics PLC (AUTL) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are neutral, options data shows minimal trading sentiment, and there are no recent positive news catalysts. Despite a significant YoY revenue increase, the company remains unprofitable with declining gross margins. Analyst ratings are positive but have lowered price targets recently, reflecting tempered expectations. Given the lack of strong growth signals and the absence of proprietary trading signals, it is best to hold off on investing in this stock for now.
The MACD is positive and expanding, indicating a slight bullish momentum. RSI is neutral at 63.262, and moving averages are converging, showing no clear trend. The stock is trading near its resistance level of 1.499, with support at 1.36. Overall, the technical indicators suggest a neutral trend.
Revenue increased significantly by 83,655.17% YoY in Q4 2025, indicating potential growth in operations. Analysts maintain a Buy rating, reflecting optimism about the company's long-term prospects.
Gross margin dropped drastically to -4.29%, and the company remains unprofitable with a net income of -$90.33M. Analyst price targets have been lowered recently, and there are no recent news or significant trading trends to support a bullish outlook. Additionally, stock trend analysis predicts a negative performance in the short term.
In Q4 2025, revenue increased to $24.29M, up 83,655.17% YoY, but the company remains unprofitable with a net income of -$90.33M. EPS improved to -0.34, up 240% YoY, but gross margin dropped to -4.29%, reflecting operational inefficiencies.
Analysts maintain a Buy rating but have lowered price targets recently. Mizuho reduced the price target to $10 from $12, and H.C. Wainwright lowered it to $8 from $11. Analysts are optimistic about the company's pipeline but cautious about near-term performance.
